BEVERLY HILLS, Calif., March 28, 2012 -- OXIS International, Inc. announced today that a Joint Pain and Mobility study demonstrating highly significant short and long-term benefits for joint health using its Patent Pending ERGOFLEX™ with proprietary EGT™ (99% pure L-ergothioneine) complex, has been published in the peer-reviewed journal, Preventive Medicine. EGT is a natural anti-oxidant, anti-inflammatory nutrient, required by humans as well as all animals, but only available through diet until now. EGT is the only known intelligent anti-oxidant to be actively transported into cells under stress. ERGOFLEX is the first dietary supplement to incorporate EGT and the only joint health complex containing this unique intelligent antioxidant. ERGOFLEX is specifically formulated to support the body's natural ability to fight the pain of joint inflammation while providing support for the structural integrity and lubrication of joints.

The study, carried out by NIS Laboratories in Klamath Falls, Oregon and presented by Gitte Jensen, PhD at the First International Congress on EGT, in July 2011 (www.ergocongress.com) was co-authored by Dr. Okezie Aruoma, PhD, DSc, MBA, is the world's leading expert on EGT. "EGT not only protects vital organs against the oxidative stress but conserves the consumption of endogenous glutathione and vitamin E," said Dr. Aruoma.

"ERGOFLEX, our first EGT-based product is an important entrant in the multi-billion dollar U.S. market for non-prescription joint health products," said David Saloff, CEO of OXIS International. "Most joint pain products only address symptoms. ERGOFLEX targets oxidative stress and inflammation, well recognized underlying issues in joint ailments," said Bernie Landes, President of OXIS.

OXIS CEO David Saloff added, "Over the coming months we plan to introduce specific EGT based products that address key health goals of not only an aging population of baby boomers, but also a younger audience seeking to maintain their youthful good health."

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT™ (99% pure L-ergothioneine), known as the intelligent antioxidant.